Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema
Qingquan Wei,1,* Zhongqi Wan,2,* Yongcheng Hu,3,* Qing Peng1 1Department of Ophthalmology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, People’s Republic of China; 2School of Public Health, Nanjing Medical University, Nanjing 211166, Jiangsu Province, Peo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-12-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/cytokine-and-chemokine-profile-changes-in-patients-after-intravitreal--peer-reviewed-article-DDDT |
| _version_ | 1811310705577558016 |
|---|---|
| author | Wei Q Wan Z Hu Y Peng Q |
| author_facet | Wei Q Wan Z Hu Y Peng Q |
| author_sort | Wei Q |
| collection | DOAJ |
| description | Qingquan Wei,1,* Zhongqi Wan,2,* Yongcheng Hu,3,* Qing Peng1 1Department of Ophthalmology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, People’s Republic of China; 2School of Public Health, Nanjing Medical University, Nanjing 211166, Jiangsu Province, People’s Republic of China; 3Department of Ophthalmology, Bayannuer Paralympic Eye Hospital, Inner Mongolia 015000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Qing PengDepartment of Ophthalmology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, People’s Republic of ChinaTel +86 13220811345Email pengqing@tongji.edu.cnPurpose: This study aimed to investigate the concentrations of cytokines and chemokines in diabetic macular edema (DME) eyes before and during therapy with the intravitreal injection of conbercept (IVC) and to identify associations with disease activity.Methods: The Bio-Plex® 200 System and the Bio-PlexTM Human Cytokine Standard 27-Plex, Group I (Bio-Rad, Hercules, California, USA) were used to detect cytokine levels in aqueous humour. Experimental aqueous humour samples were collected from 18 patients with DME at the same time that IVC was performed at baseline and at 1 month. Control aqueous humour samples were collected from 16 patients undergoing cataract surgery.Results: Significantly higher concentrations of vascular endothelial growth factor (VEGF), interleukin 6 (IL-6), IL-8, eotaxin, granulocyte colony stimulating factor (G-CSF), interferon gamma-induced protein 10 (IP-10), and monocyte chemoattractant protein-1 (MCP-1) were found in the aqueous humour of DME patients than cataract patients. One month after IVC, the intraocular concentrations of VEGF were significantly lower in the eyes of DME patients than at baseline. No other cytokines were significantly altered by conbercept therapy. Best-corrected visual acuity (BCVA) slightly improved following IVC compared with that at baseline, although this difference was not significant, and central macular thickness (CMT) significantly decreased 1 month after IVC treatment.Conclusion: Angiogenic, inflammatory and growth factors are involved in the development of DME. With the exception of VEGF, IVC did not cause significant differences in any inflammatory cytokines or growth factors in DME patients. CMT is related to VEGF levels in aqueous humour.Keywords: diabetic macular oedema, conbercept, intravitreal implant, intraocular cytokines |
| first_indexed | 2024-04-13T10:03:40Z |
| format | Article |
| id | doaj.art-14ea634c4b034fc9a06a340cb7542df2 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-13T10:03:40Z |
| publishDate | 2019-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-14ea634c4b034fc9a06a340cb7542df22022-12-22T02:51:09ZengDove Medical PressDrug Design, Development and Therapy1177-88812019-12-01Volume 134367437450677Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular EdemaWei QWan ZHu YPeng QQingquan Wei,1,* Zhongqi Wan,2,* Yongcheng Hu,3,* Qing Peng1 1Department of Ophthalmology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, People’s Republic of China; 2School of Public Health, Nanjing Medical University, Nanjing 211166, Jiangsu Province, People’s Republic of China; 3Department of Ophthalmology, Bayannuer Paralympic Eye Hospital, Inner Mongolia 015000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Qing PengDepartment of Ophthalmology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, People’s Republic of ChinaTel +86 13220811345Email pengqing@tongji.edu.cnPurpose: This study aimed to investigate the concentrations of cytokines and chemokines in diabetic macular edema (DME) eyes before and during therapy with the intravitreal injection of conbercept (IVC) and to identify associations with disease activity.Methods: The Bio-Plex® 200 System and the Bio-PlexTM Human Cytokine Standard 27-Plex, Group I (Bio-Rad, Hercules, California, USA) were used to detect cytokine levels in aqueous humour. Experimental aqueous humour samples were collected from 18 patients with DME at the same time that IVC was performed at baseline and at 1 month. Control aqueous humour samples were collected from 16 patients undergoing cataract surgery.Results: Significantly higher concentrations of vascular endothelial growth factor (VEGF), interleukin 6 (IL-6), IL-8, eotaxin, granulocyte colony stimulating factor (G-CSF), interferon gamma-induced protein 10 (IP-10), and monocyte chemoattractant protein-1 (MCP-1) were found in the aqueous humour of DME patients than cataract patients. One month after IVC, the intraocular concentrations of VEGF were significantly lower in the eyes of DME patients than at baseline. No other cytokines were significantly altered by conbercept therapy. Best-corrected visual acuity (BCVA) slightly improved following IVC compared with that at baseline, although this difference was not significant, and central macular thickness (CMT) significantly decreased 1 month after IVC treatment.Conclusion: Angiogenic, inflammatory and growth factors are involved in the development of DME. With the exception of VEGF, IVC did not cause significant differences in any inflammatory cytokines or growth factors in DME patients. CMT is related to VEGF levels in aqueous humour.Keywords: diabetic macular oedema, conbercept, intravitreal implant, intraocular cytokineshttps://www.dovepress.com/cytokine-and-chemokine-profile-changes-in-patients-after-intravitreal--peer-reviewed-article-DDDTdiabetic macular oedemaconberceptintravitreal implantintraocular cytokines |
| spellingShingle | Wei Q Wan Z Hu Y Peng Q Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema Drug Design, Development and Therapy diabetic macular oedema conbercept intravitreal implant intraocular cytokines |
| title | Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema |
| title_full | Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema |
| title_fullStr | Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema |
| title_full_unstemmed | Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema |
| title_short | Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema |
| title_sort | cytokine and chemokine profile changes in patients after intravitreal conbercept injection for diabetic macular edema |
| topic | diabetic macular oedema conbercept intravitreal implant intraocular cytokines |
| url | https://www.dovepress.com/cytokine-and-chemokine-profile-changes-in-patients-after-intravitreal--peer-reviewed-article-DDDT |
| work_keys_str_mv | AT weiq cytokineandchemokineprofilechangesinpatientsafterintravitrealconberceptinjectionfordiabeticmacularedema AT wanz cytokineandchemokineprofilechangesinpatientsafterintravitrealconberceptinjectionfordiabeticmacularedema AT huy cytokineandchemokineprofilechangesinpatientsafterintravitrealconberceptinjectionfordiabeticmacularedema AT pengq cytokineandchemokineprofilechangesinpatientsafterintravitrealconberceptinjectionfordiabeticmacularedema |